Table 4.
Chemotherapeutic agents and concomitant use of sorafenib for first‐line TACE
| All stages | Early stages | Advanced stages | P | |
|---|---|---|---|---|
| (N = 4283) | (N = 2940) | (N = 1343) | ||
| Epirubicin | 44.1% | 45.3% | 41.6% | 0.026 |
| Miriplatin | 23.6% | 24.6% | 21.4% | 0.020 |
| Cisplatin | 12.3% | 11.1% | 15.0% | <0.001 |
| Epirubicin and mitomycin C | 8.5% | 8.5% | 8.5% | 1.000 |
| Doxorubicin | 2.9% | 2.8% | 3.3% | 0.381 |
| Doxorubicin and mitomycin C | 1.9% | 2.1% | 1.3% | 0.089 |
| Cisplatin and miriplatin | 1.8% | 1.7% | 2.0% | 0.539 |
| Concomitant use of sorafenib | 3.2% | 1.5% | 6.9% | <0.001 |
The differences in mean values between early and advanced stages were assessed and P‐values were calculated using Fisher's exact test. TACE, transcatheter arterial chemoembolization.